Balestrini et al. show the identification of a TRPA1 inhibitor that suppresses airway smooth muscle contraction, inflammation, edema, and cough in preclinical models and show target engagement in humans, demonstrating that pharmacologic inhibition of TRPA1 is a promising therapy for asthma.
A TRPA1 inhibitor suppresses neurogenic inflammation and airway contraction for asthma treatment
A. Balestrini,Victory Joseph,M. Dourado,Rebecca M. Reese,S. Shields,L. Rougé,Daniel D. Bravo,T. Chernov-Rogan,Cary D. Austin,Huifen Chen,Lan Wang,Elisia Villemure,D. Shore,Vishal A. Verma,Baihua Hu,Yong Chen,Laurie Leong,C. Bjornson,K. Hötzel,Alvin Gogineni,Wyne P. Lee,Eric Suto,Xiumin Wu,John Liu,Juan Zhang,V. Gandham,Jianyong Wang,J. Payandeh,C. Ciferri,A. Estevez,C. Arthur,Jens Kortmann,R. Wong,Jose E. Heredia,Jonas Doerr,Min-Yeong Jung,J. V. Vander Heiden,Merone Roose-Girma,Lucinda Tam,K. Barck,R. Carano,H. Ding,B. Brillantes,C. Tam,Xiaoying Yang,Simon S. Gao,J. Ly,Liling Liu,Liuxi Chen,B. Liederer,Joseph Lin,Steven Magnuson,Jun Chen,D. Hackos,J. Elstrott,A. Rohou,B. Safina,M. Volgraf,R. Bauer,Lorena Riol-Blanco
Published 2021 in Journal of Experimental Medicine
ABSTRACT
PUBLICATION RECORD
- Publication year
2021
- Venue
Journal of Experimental Medicine
- Publication date
2021-02-23
- Fields of study
Medicine
- Identifiers
- External record
- Source metadata
Semantic Scholar, PubMed
CITATION MAP
EXTRACTION MAP
CLAIMS
- No claims are published for this paper.
CONCEPTS
- No concepts are published for this paper.